Amantadine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Amantadine

Examples of brand names: PK-Merz [DE]

ATC code: N04BB01

Main use (for orientation): Parkinson's disease

Documented research summary

Older rat studies report attenuation of THC-induced catalepsy by amantadine (1985/2008), not clinically confirmed. Amantadine–CBD conjugates are new chemical carrier molecules, not co-medication with free CBD/amantadine.

Uncertainties and limitations

Documented individual title/abstract review with selected relevant full texts; not an exhaustive worldwide systematic review and no independent human professional approval. Missing data do not establish safety. All 28 cannabinoids define the search scope, not 28 clinically studied pairs per active substance.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

THC – laboratory and animal studies

Finding ID: B0484

Type of result: Context-specific finding

Observation: Amantadine attenuated THC-associated catalepsy/immobility and some other behavioural endpoints in different models.

Mechanism: Dopaminergic and other central signalling pathways influence THC-related motor changes.

Study type: Rat models, pharmacodynamics

Context studied: Two historical original abstracts; distinguish systemic and local THC-model contexts.

Clinical interpretation: Applicability to humans is unresolved; preclinical endpoint, not clinical evidence of treatment efficacy or safety.

Limitations and uncertainties: No clinical amantadine–cannabis drug–drug interaction. Conjugated new amantadine–CBD molecules are not co-administration and are not included here.

Original sources for this finding: [Behavioral pharmacology of amantadine with special references to the effect on abnormal behavior in mice and rats]. [VF_P_2989132]; Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. [VF_P_18083311]

References and access status

[VF_L_D0425] GOCOVRI (AMANTADINE) CAPSULE, COATED PELLETS [SUPERNUS PHARMACEUTICALS, INC.]

Original source / bibliographic reference

Authors: Marketing authorisation holder; official product information via DailyMed

Year: 2026

Source type: Official medicine information; relevant identity, PK, PD and DDI sections read individually

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VF_P_18083311] Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons.

Original source / bibliographic reference

Authors: Sano K, Mishima K, Koushi E, Orito K, Egashira N, Irie K, Takasaki K, Katsurabayashi S, Iwasaki K, Uchida N, Egawa T, Kitamura Y, Nishimura R, Fujiwara M.

Year: 2008

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.1016/j.neuroscience.2007.10.026

PMID: 18083311

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[VF_P_2989132] [Behavioral pharmacology of amantadine with special references to the effect on abnormal behavior in mice and rats].

Original source / bibliographic reference

Authors: Fujiwara M, Sakurai Y, Kiyota Y, Shimazoe T, Ohta H, Shibata S, Ueki S.

Year: 1985

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.1254/fpj.85.259

PMID: 2989132

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility